Learn from experts in the field as they discuss barriers and key strategies for developing and conducting an MUE for the direct oral anticoagulant reversal agent, andexanet alfa. In addition to sharing the process for building a meaningful MUE, presenters will provide insights into navigating medication use evaluations with clinical controversy and local considerations.
SPEAKERS
Charles Pollack, MA, MD, is a clinician-scientist in the Department of Emergency Medicine at the University of Mississippi Medical Center. Pollack has practiced emergency medicine in an academic setting for nearly forty years. He has published more than 500 articles and chapters and has been recognized with multiple awards in his specialty for both his teaching and his research, particularly in the area of thrombosis and anti-thrombotic therapy. A member of ASHP, he is an advocate for multidisciplinary collaboration involving emergency medicine in both patient care and research.
Jessica Grandoni, PharmD, BCPS, was the hemostatic antithrombotic stewardship lead pharmacist and clinical pharmacy specialist at Brigham and Women’s Hospital in Boston, Massachusetts. She is now a clinical pharmacy specialist at the Dana Farber Cancer Institute’s Anticoagulation Management Service facilitating care for cancer patients requiring anticoagulation. Jessica has been involved in several committees and initiatives related to her practice interests of anticoagulation therapy and reversal. She is involved in research, education, and quality improvement.
John Fanikos, RPh, MBA, is Chief of Pharmacy Services at Brigham and Women's Hospital in Boston, Massachusetts. He is responsible for Pharmacy Department operations and its financial performance. He has worked closely with the hospital’s Thromboembolism Research Group authoring and co-authoring many articles and textbook chapters with an emphasis on medication utilization, avoiding the medication problems and pitfalls of medication use, and optimizing patient safety.
